Antiobesity activity of pluronic L-101.
Pluronic L-101, a hydrophobic surface-active agent, was a potent in-vitro inhibitor of human pancreatic lipase. When administered as a 1 percent or 3 percent dietary admix to meal-fed rats, pluronic L-101 produced a significant and dose-dependent decrease in body-weight gain while not affecting food consumption. Excretion of dietary fat in the feces was enhanced significantly in a dose-dependent manner during pluronic L-101 treatment. Pluronic F-68, a hydrophilic surface-active agent which was a poor in-vitro inhibitor of human pancreatic lipase, did not produce decreases in body-weight gain or increase fecal-fat excretion in rats. The decreased body-weight gain produced by pluronic L-101 was reflected in a decreased percentage of carcass fat; the percentage of carcass protein was unchanged. Liver wet weight was reduced significantly only at the 3 percent pluronic L-101 level. Serum levels of cholesterol, triglyceride and glucose remained unchanged. During pluronic L-101 treatment no overt signs of toxicity were observed.
D000042:Absorption; D000273:Adipose Tissue / Q000378:metabolism; D000818:Animals; D001835:Body Weight / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000187:drug effects; D005227:Fatty Acids / Q000378:metabolism; D005260:Female; D006801:Humans; D008049:Lipase / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D009929:Organ Size; D010179:Pancreas / Q000201:enzymology; D011060:Poloxalene / Q000008:administration & dosage / Q000494:pharmacology*; D011092:Polyethylene Glycols / Q000494:pharmacology*; D051381:Rats
D005227:Fatty Acids; D011092:Polyethylene Glycols; D011060:Poloxalene; D008049:Lipase